Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

Cited In for PubMed (Select 17264329)


Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.

Huang CY, Chang MC, Huang WY, Huang CT, Tang YC, Huang HD, Kuo KT, Chen CA, Cheng WF.

Sci Rep. 2015 Jun 2;5:10680. doi: 10.1038/srep10680.


Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.

Gilder AS, Jones KA, Hu J, Wang L, Chen CC, Carter BS, Gonias SL.

J Biol Chem. 2015 Jun 12;290(24):14798-809. doi: 10.1074/jbc.M115.637488. Epub 2015 Apr 2.


Imaging active urokinase plasminogen activator in prostate cancer.

LeBeau AM, Sevillano N, Markham K, Winter MB, Murphy ST, Hostetter DR, West J, Lowman H, Craik CS, VanBrocklin HF.

Cancer Res. 2015 Apr 1;75(7):1225-35. doi: 10.1158/0008-5472.CAN-14-2185. Epub 2015 Feb 11.


Molecular regulation of bone marrow metastasis in prostate and breast cancer.

Rahim F, Hajizamani S, Mortaz E, Ahmadzadeh A, Shahjahani M, Shahrabi S, Saki N.

Bone Marrow Res. 2014;2014:405920. doi: 10.1155/2014/405920. Epub 2014 Jul 23. Review.


Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer.

Banyard J, Chung I, Migliozzi M, Phan DT, Wilson AM, Zetter BR, Bielenberg DR.

BMC Cancer. 2014 May 30;14:387. doi: 10.1186/1471-2407-14-387.


Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.

Al-Janabi O, Taubert H, Lohse-Fischer A, Fröhner M, Wach S, Stöhr R, Keck B, Burger M, Wieland W, Erdmann K, Wirth MP, Wullich B, Baretton G, Magdolen V, Kotzsch M, Füssel S.

Biomed Res Int. 2014;2014:972587. doi: 10.1155/2014/972587. Epub 2014 Apr 29.


Novel tools for prostate cancer prognosis, diagnosis, and follow-up.

Dimakakos A, Armakolas A, Koutsilieris M.

Biomed Res Int. 2014;2014:890697. doi: 10.1155/2014/890697. Epub 2014 May 4. Review.


Recent advances in bone-targeted therapies of metastatic prostate cancer.

Deng X, He G, Liu J, Luo F, Peng X, Tang S, Gao Z, Lin Q, Keller JM, Yang T, Keller ET.

Cancer Treat Rev. 2014 Jul;40(6):730-8. doi: 10.1016/j.ctrv.2014.04.003. Epub 2014 Apr 16. Review.


Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model.

Landowski TH, Gard J, Pond E, Pond GD, Nagle RB, Geffre CP, Cress AE.

Mol Cancer Ther. 2014 Jun;13(6):1558-66. doi: 10.1158/1535-7163.MCT-13-0962. Epub 2014 Apr 16.


Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era.

Chen J, Zhang D, Yan W, Yang D, Shen B.

Biomed Res Int. 2013;2013:901578. doi: 10.1155/2013/901578. Epub 2013 Jul 15. Review.


The present and future of prostate cancer urine biomarkers.

Rigau M, Olivan M, Garcia M, Sequeiros T, Montes M, Colás E, Llauradó M, Planas J, Torres Id, Morote J, Cooper C, Reventós J, Clark J, Doll A.

Int J Mol Sci. 2013 Jun 17;14(6):12620-49. doi: 10.3390/ijms140612620.


First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.

Persson M, Liu H, Madsen J, Cheng Z, Kjaer A.

Nucl Med Biol. 2013 Jul;40(5):618-24. doi: 10.1016/j.nucmedbio.2013.03.001. Epub 2013 Apr 18.


Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model.

Hafeez BB, Zhong W, Fischer JW, Mustafa A, Shi X, Meske L, Hong H, Cai W, Havighurst T, Kim K, Verma AK.

Mol Oncol. 2013 Jun;7(3):428-39. doi: 10.1016/j.molonc.2012.12.001. Epub 2012 Dec 14.


Cell surface remodeling by plasmin: a new function for an old enzyme.

Deryugina EI, Quigley JP.

J Biomed Biotechnol. 2012;2012:564259. doi: 10.1155/2012/564259. Epub 2012 Oct 14. Review.


Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.

McKee CM, Xu D, Cao Y, Kabraji S, Allen D, Kersemans V, Beech J, Smart S, Hamdy F, Ishkanian A, Sykes J, Pintile M, Milosevic M, van der Kwast T, Zafarana G, Ramnarine VR, Jurisica I, Mallof C, Lam W, Bristow RG, Muschel RJ.

J Clin Invest. 2012 Nov;122(11):4025-36. doi: 10.1172/JCI59348. Epub 2012 Oct 8.


Gelsolin induces colorectal tumor cell invasion via modulation of the urokinase-type plasminogen activator cascade.

Zhuo J, Tan EH, Yan B, Tochhawng L, Jayapal M, Koh S, Tay HK, Maciver SK, Hooi SC, Salto-Tellez M, Kumar AP, Goh YC, Lim YC, Yap CT.

PLoS One. 2012;7(8):e43594. doi: 10.1371/journal.pone.0043594. Epub 2012 Aug 21.


Soluble interleukin-6 receptor to interleukin-6 (sIL‑6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy.

Terracciano D, Bruzzese D, Ferro M, Autorino R, di Lorenzo G, Buonerba C, Mariano A, Macchia V, Altieri V, di Carlo A.

Oncol Lett. 2011 Sep 1;2(5):861-864. Epub 2011 Jul 4.


Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.

Bekes EM, Deryugina EI, Kupriyanova TA, Zajac E, Botkjaer KA, Andreasen PA, Quigley JP.

Neoplasia. 2011 Sep;13(9):806-21.


Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.

Sroka IC, Sandoval CP, Chopra H, Gard JM, Pawar SC, Cress AE.

Mol Cancer Res. 2011 Oct;9(10):1319-28. doi: 10.1158/1541-7786.MCR-11-0080. Epub 2011 Aug 8.


Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances.

Liu X, Kolokythas A, Wang J, Huang H, Zhou X.

Curr Cancer Ther Rev. 2010 Nov 1;6(4):294-307.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk